ROIV Stock Price Today (September 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-09-03
Roivant Sciences Ltd. (ROIV) is trading at $34.41, up 0.67% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $41.86 (21.7% upside).
- Volatility remains elevated (33.18% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-33.50% YoY) alongside significant competitive pressures.
ROIV Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $22.03B
P/E Ratio
Forward P/E: -20.17
Revenue Growth
Year over Year
Analyst Target
+21.7% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 39.67)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $107.15M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $11.94 and $37.97—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 33.18% annualized volatility and β=0.93, the stock exhibits moderate correlation to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch. Matt Gline, Roivant’s CEO, called the approval a significant milestone for patients w
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?
Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per share highlights Roivant’s ongoing effort to manage costs while progressing its inflammation and immunology portfolio. We’ll now examine how this combination of reduced sales and a smaller quarterly net loss could...
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?
Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the period ended June 30, 2026. Sales were US$1.44 million, while the company reported a net loss of US$189.84 million. The loss from continuing operations translated into a basic loss per share of US$0.26. Investors are now weighing how these figures, together with the updated loss profile, fit into the broader story for this clinical stage...
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary
Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call
Roivant Sciences Q1 Earnings Call Highlights
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie
Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...
Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus expects to receive around $179 million from Moderna.
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Wall Street expects sales to soar as several commercial launches approach.
Explore More Analysis for ROIV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $34.41. The RSI (14-day) is at 39.7, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $41.86 implies 21.7% upside from current levels. Volatility is moderate at 33.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is -73.21, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -20.17. Price-to-Book is 5.88. Price-to-Sales is 3299.94. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ROIV, the consensus price target is $41.86. This represents a 21.7% upside from the current price of $34.41. The range spans from a low target of $37.50 to a high target of $50.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. Moderate volatility (33.2% annualized)—price swings are notable. 2. Declining revenue (-33.5% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $107.15M. The debt-to-equity ratio is 2.18, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 16.72, indicating strong short-term liquidity. The quick ratio is 13.62. The company holds $3.84B in cash and equivalents. Free cash flow is negative at $-1,127,230,080, which could limit the company's ability to manage debt obligations.